NYC Neuromodulation 2017 will focus on technologies and mechanism for advanced brain stimulation in areas that include transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), transcranial magnetic stimulation (TMS), high-definition transcranial direct current stimulation (HD-tDCS), electroconvulsive therapy (ECT), deep brain stimulation (DBS), and other emerging areas. Applications span treatment of neuropsychiatric disorders, neurorehabilitation, and performance enhancement. Interactive lectures from key opinion leaders and emerging young scientists, poster sessions with abstracts published in Brain Stimulation and extensive opportunities to network with colleagues, along with an exhibit showcase featuring the latest neuromodulation technologies are all part of the main conference agenda.
This conference is among the most forward-looking neuromodulation meetings with the goal of advancing innovation from bench-top to bedside and home. Given the increased media, public, and commercial interest in personal non-invasive brain stimulation, the 2017 meeting will emphasize emerging “consumer” technologies, and their scientific and regulatory barriers. The off-label use of new clinical protocols will be addressed from scientific, medical, and regulatory perspectives. The conference will also focus on timely and novel targets of neuromodulation including glia, as well as new waveforms including high-rate (10 kHz) stimulation. Representatives from funding agencies and journal editors will be available to discuss priorities. NYC Neuromodulation is the largest meeting focused on non-invasive neuromodulation in North America, but this year it considers the role of invasive and non-invasive techniques in the continuum of care.
Chair: Marom Bikson